Cochrane · systematic review · CD007020
Antioxidant supplementation for lung disease in cystic fibrosis
Ciofu, O, Smith, S, Lykkesfeldt, J · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
14
No studies
22
Included studies
NR
No studies 22 · 61.1%Ungraded 0 · 0%Very low 3 · 8.3%Low 4 · 11.1%Moderate 7 · 19.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: oral antioxidants (NAC/GSH) compared to placebo
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidants (NAC/GSH) vs placebo | no estimate extracted | 4 studies · 125 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidants (NAC/GSH) vs placebo | no estimate extracted | 1 study · 62 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Quality of life: change in mean CFQ‐R score from baseline Summary of findings: oral antioxidants (NAC/GSH) vs placebo | no estimate extracted | 1 study · 61 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Nutritional status: change from baseline in BMI Summary of findings: oral antioxidants (NAC/GSH) vs placebo | no estimate extracted | 1 study · 62 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: oral antioxidants (NAC/GSH) vs placebo | no estimate extracted | NR | No studies |
Adverse events Summary of findings: oral antioxidants (NAC/GSH) vs placebo | OR 2.92 [0.11, 74.05] | 1 study · 70 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings: oral vitamin E supplementation versus placebo or no treatment
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral vitamin E supplementation vs placebo or no treatment | no estimate extracted | NR | No studies |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral vitamin E supplementation vs placebo or no treatment | no estimate extracted | NR | No studies |
Quality of life Summary of findings: oral vitamin E supplementation vs placebo or no treatment | no estimate extracted | NR | No studies |
Nutritional status: change from baseline in BMI Summary of findings: oral vitamin E supplementation vs placebo or no treatment | no estimate extracted | NR | No studies |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: oral vitamin E supplementation vs placebo or no treatment | no estimate extracted | NR | No studies |
Adverse events Summary of findings: oral vitamin E supplementation vs placebo or no treatment | OR 1 [0.13, 7.94] | 1 study · 38 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: oral β‐carotene compared to placebo
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral β‐carotene vs placebo | no estimate extracted | NR | No studies |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral β‐carotene vs placebo | no estimate extracted | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Quality of life Summary of findings: oral β‐carotene vs placebo | no estimate extracted | NR | No studies |
Nutritional status: change from baseline in BMI Summary of findings: oral β‐carotene vs placebo | no estimate extracted | NR | No studies |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: oral β‐carotene vs placebo | no estimate extracted | NR | No studies |
Adverse events Summary of findings: oral β‐carotene vs placebo | no estimate extracted | 1 study · 24 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Summary of findings: oral antioxidant combination compared to control
Population: children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Quality of life: Quality of Well Being score change from baseline Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Nutritional status: change from baseline in BMI Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Adverse events Summary of findings: oral antioxidant combination vs control | no estimate extracted | NR | No studies |
Summary of findings: oral antioxidant mixed supplement compared with control
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | NR | No studies |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | NR | No studies |
Quality of life: Quality of Well Being score change from baseline Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | NR | No studies |
Nutritional status: change from baseline in BMI Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | NR | No studies |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | 1 study · 69 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Summary of findings: oral antioxidant mixed supplement vs control | no estimate extracted | 1 study · 69 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: inhaled antioxidants compared with placebo
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function: FEV1 % predicted mean change from baseline Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | 3 studies · 258 participants | Moderate Downgraded: risk of bias, imprecision |
Lung function: FEV1 % predicted mean change from baseline Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | 3 studies · 258 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life: change in CFQoL score from baseline Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | 1 study · 153 participants | Moderate Downgraded: risk of bias, imprecision |
Nutritional status: change from baseline in BMI Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | NR | No studies |
Pulmonary exacerbations: mean time to next exacerbation Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | NR | No studies |
Adverse events Summary of findings: inhaled antioxidants vs placebo | no estimate extracted | 3 studies · 223 participants | Low Downgraded: risk of bias, imprecision |